Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure

2023-09-26
WALTHAM, Mass., September 26, 2023--Revvity, Inc., (NYSE: RVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories. Base editing represents a pivotal advancement in CRISPR gene editing, providing the capability for complex and safe multi-gene editing, which can result in enhanced functional genomics insights for optimizing drug development, as

Revvity expands access to base editing technology

2023-09-26
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing?

2023-09-17
Revvity, Inc. ( NYSE:RVTY ) received a lot of attention from a substantial price movement on the NYSE over the last few...

Agree To Buy Revvity At $95, Earn 4.8% Annualized Using Options

2023-09-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Stocks That Hit 52-Week Lows On Monday

2023-09-11
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Stocks That Hit 52-Week Lows On Friday

2023-09-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Friday Sector Laggards: Healthcare, Industrial

2023-09-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Revvity (RVTY)'s True Worth: A Comprehensive Analysis of Its Market Value

2023-09-06
Is Revvity (RVTY) fairly valued? Let's delve into its intrinsic value, financial strength, profitability, and growth prospects.

Revvity (RVTY) Launches Three New Preclinical Research Systems

2023-09-06
Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.

Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

2023-09-05
WALTHAM, Mass., September 05, 2023--Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries